Hemostemix Inc. (CVE:HEM – Get Free Report) shares shot up 29.4% during trading on Friday . The stock traded as high as C$0.11 and last traded at C$0.11. 602,760 shares were traded during mid-day trading, an increase of 511% from the average session volume of 98,700 shares. The stock had previously closed at C$0.09.
Hemostemix Stock Performance
The stock has a fifty day simple moving average of C$0.09 and a 200-day simple moving average of C$0.10. The stock has a market cap of C$20.73 million, a P/E ratio of -4.07 and a beta of 1.25. The company has a debt-to-equity ratio of -55.07, a quick ratio of 0.48 and a current ratio of 0.04.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
See Also
- Five stocks we like better than Hemostemix
- NEW LAW: Congress Approves Setup For Digital Dollar?
- Do not delete, read immediately
- A month before the crash
- Claim Your Share of $5.39 BILLION in AI Equity Checks
- If You Keep Cash In A U.S. Bank Account… Read This NOW
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
